key: cord-0977703-vcrk9mnv
authors: Martins‐Filho, Paulo Ricardo; do Nascimento‐Júnior, Edmundo Marques; Santana Santos, Victor
title: No current evidence supporting risk of using Ibuprofen in patients with COVID‐19
date: 2020-06-07
journal: Int J Clin Pract
DOI: 10.1111/ijcp.13576
sha: a1b137661fabecdfab75dd21df1cb2c8487cb2df
doc_id: 977703
cord_uid: vcrk9mnv

SARS‐CoV‐2 is a novel RNA virus that infects cells expressing the angiotensin‐converting enzyme (ACE2) receptor and is associated with an acute respiratory disease named COVID‐19. It has been hypothesized that ACE2 expression can be increased by Ibuprofen leading to a higher risk for severe COVID‐19 (1). Despite the reasonable mechanistic background and results from studies suggesting that Ibuprofen may be associated with complications of community‐acquired pneumonia in children (2,3), there is no current evidence that this NSAID aggravates a SARS‐CoV‐2 infection in any age group.

SARS-CoV-2 is a novel RNA virus that infects cells expressing the angiotensin-converting enzyme (ACE2) receptor and is associated with an acute respiratory disease named COVID-19. It has been hypothesized that ACE2 expression can be increased by Ibuprofen leading to a higher risk for severe COVID-19 (1). Despite the reasonable mechanistic background and results from studies suggesting that Ibuprofen may be associated with complications of community-acquired pneumonia in children (2, 3) , there is no current evidence that this NSAID aggravates a SARS-CoV-2 infection in any age group.

It is possible that potential negative outcomes related to patients using Ibuprofen to relieve respiratory symptoms are more likely to be observed due to a more severe infection rather than the drug, which is known as reverse causality bias (4) . In fact, the use of Ibuprofen and its effects on ACE2 expression in patients with SARS-CoV-2 infection remains an important and controversial issue. Despite animal models have found that Ibuprofen can enhance the ACE2 expression (5) and theoretically facilitate binding, internalization and viral infection, a recent paper (6) suggested that the mechanism of lung injury during the SARS-CoV-2 infection may be through inappropriate effects of excess free angiotensin-II protein as a consequence of ACE2 downregulation leading to over-stimulation of AT1 receptor (AT1R), pulmonary vasoconstriction in response to hypoxia, increased vascular tone and subsequent hydrostatic edema formation. Angiotensin-II is recognized to act as a powerful proinflammatory mediator through stimulation of AT1R (7, 8) and has been implicated in the pathogenesis of acute respiratory distress syndrome (ARDS) (9), a condition commonly found in patients with critical COVID-19. Although it seems counter-intuitive, it has been suggested that a higher ACE2 expression followed by the use of AT1R antagonists may result to production of the vasodilator angiotensin 1-7 and protect against acute injury (6) . Therefore, in this hypothetical scenario, it is paradoxically reasonable to assume that Ibuprofen can have positive effects against SARS-CoV-2 if used in conjunction with AT1R antagonists. To date, there is more speculation than robust scientific evidence that points to the true effect of NSAIDs, especially Ibuprofen, on COVID-19. Therefore, further studies are urgently needed to Accepted Article

Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection?

Risk factors for local complications in children with community-acquired pneumonia

Prevalence and risk factors of suppurative complications in children with pneumonia

Safety of Ibuprofen in Patients with COVID-19; Causal or Confounded? Chest

Ibuprofen attenuates cardiac fibrosis in streptozotocin-induced diabetic rats

Angiotensin receptor blockers as tentative SARS-CoV-2 therapeutics

Role of the renin-angiotensin system in vascular inflammation

Inflammation and angiotensin II

The discovery of angiotensin-converting enzyme 2 and its role in acute lung injury in mice

This article is protected by copyright. All rights reserved